- Tetra Bio-Pharma (TSXV:TBP) has provided an update on its clinical trial, which will test drug PPP003 against animal eye diseases.
- The company’s operational manufacturing suite will produce sterile batches of the cannabinoid drug for testing.
- The planned clinical trial for companion animals will begin in 2020.
- Tetra hopes to bring PPP0003 to human clinical trials later this year.
- Tetra Bio-Pharma’s share price is up 1.02 per cent, with shares trading at $0.50 apiece.
Biopharmaceutical company Tetra Bio-Pharma Inc (TBP) has provided an update on its clinical trial, which will test the company’s PPP003 drug.
Tetra’s subsidiary, Panag Pharma, is ready to begin the treatment phase of the trial. The trial will evaluate how well cannabinoid-derived PPP003 will treat painful canine eye conditions, like indolent corneal ulcers.
Since Health Canada gave them authorisation last year, Tetra has set up a manufacturing suite at the facility in New Brunswick.
The operational facility will produce batches of the sterile drug, for use in the animal trial scheduled to begin this year.
Another manufacturing facility or suite may be constructed later, if clinical trials for human patients begin. Hopes are high that cannabinoid-derived drugs like PPP003 may treat human eye diseases, like dry eye and uveitis.
Dr Guy Chamberland, CEO and Chief Regulatory Office of Tetra Bio-Pharma, commented on the developments. “In June 2019, the U.S. FDA validated our ophthalmic research program. […] With that milestone achieved, we are in an excellent position to bring PPP003 to human clinical trials this year.”
“This drug development program is one of Tetra’s corporate priorities, since there is a significant unmet medical need for ophthalmic drugs in both companion animals and humans.”
Tetra Bio-Pharma’s share price is up 1.02 per cent, with shares trading at $0.50 apiece.